Insulin

Ozempic Type 2 Diabetes Management Medication Readily Available From Canada Pharmacy

Retrieved on: 
Wednesday, January 11, 2023
Pancreas, Blood, A1C, Attention, Weight loss, Insulin, Diabetes, Appetite, Stomach, Type 2 diabetes, Food, Pharmaceutical industry, Semaglutide

Ozempic is the newer Type 2 diabetes medication that has the most fanfare these days and is only injected once per month.

Key Points: 
  • Ozempic is the newer Type 2 diabetes medication that has the most fanfare these days and is only injected once per month.
  • Canada Pharmacy can fill Ozempic prescriptions for US residents.
  • So why is Ozempic getting so much attention, and why are so many Type 2 diabetics keen to switch to Ozempic or Wegory?
  • Americans can order Ozempic from Canada Pharmacy if affording the Type 2 diabetes medication that suits their aims best is difficult, and evaluating options for finding the best price on Ozempic 2.0mg is advisable for anyone who is starting on Ozempic.

MD Process Launches a New Approach to Blood Sugar Health, GlucoBerry(TM)

Retrieved on: 
Thursday, December 22, 2022
Patient, Aristotelia chilensis, Health, Safety, Insulin, MD, Pharmaceutical industry

Atlanta, Georgia--(Newsfile Corp. - December 22, 2022) - Health formula developer MD Process launches GlucoBerry™, a unique approach to blood sugar health with a proprietary formula based on the Maqui Berry extract.

Key Points: 
  • Atlanta, Georgia--(Newsfile Corp. - December 22, 2022) - Health formula developer MD Process launches GlucoBerry™, a unique approach to blood sugar health with a proprietary formula based on the Maqui Berry extract.
  • Maqui berry extract helps blood sugar through its antioxidant effects, specifically by supporting the kidneys in properly filtering sugar out of the bloodstream.
  • This process helps prevent sugar from reaching the kidneys and then being "sent back" into the bloodstream.
  • Proper flushing of excess sugar allows other blood sugar regulation mechanisms like insulin to perform their functions more effectively.

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Retrieved on: 
Wednesday, January 4, 2023
Diabetes, Partnership, Harvard Medical School, Trinity University, Associate, Insulin, Bionics, Human, Joslin Diabetes Center, MD, Research, Knowledge, Type 2 diabetes, Meal, Ilet, University of Texas Southwestern Medical Center, Endocrinology, T1D, Metabolism, Boston University, Massachusetts General Hospital, Internal medicine, MGH, University, FDA, Fatty liver disease, Ageing, Hospital, Sale, Biochemistry, Pharmaceutical industry, Medical device, Medicine

CONCORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company — announced the appointment of Steven Russell, MD, Ph.D., to the role of Chief Medical Officer as the company prepares for the commercial launch of the iLet Bionic Pancreas System.

Key Points: 
  • CONCORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company — announced the appointment of Steven Russell, MD, Ph.D., to the role of Chief Medical Officer as the company prepares for the commercial launch of the iLet Bionic Pancreas System.
  • "As we move closer to commercial launch of the iLet Bionic Pancreas, we have strategically added a wealth of knowledge and experience to our executive team," explained Sean Saint, President and CEO of Beta Bionics.
  • There is no better person we could have for our Chief Medical Officer as we complete the regulatory review process and prepare for the U.S. launch of the iLet."
  • "I am thrilled to welcome Steven to Beta Bionics as our new Chief Medical Officer," said Ed Damiano, Ph.D., Founder and Executive Chair of Beta Bionics.

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219

Retrieved on: 
Wednesday, January 4, 2023
PD, Cancer, Pancreas, Adequate stimulus, Pharmacokinetics, Insulin, Patient, Safety, FDA, IND, Phase, Diabetes, Pharmaceutical industry

“We are thrilled to announce this milestone so soon after receiving IND clearance from the FDA in December.

Key Points: 
  • “We are thrilled to announce this milestone so soon after receiving IND clearance from the FDA in December.
  • BMF-219 is potentially capable of addressing and modifying a major driver of type 2 diabetes, beta cell health and function.
  • Low beta cell mass is a root cause of type 2 diabetes; without enough healthy, functional beta cells, people with type 2 diabetes are unable to produce sufficient amounts of insulin.
  • Preclinical studies have shown the potential of BMF-219 to restore and balance beta cells mass.

HealthEd Academy Reports On The Latest Ketogenic Diet Study And Its Link To Boosting Testosterone By 25%

Retrieved on: 
Tuesday, December 20, 2022
Manchester Health Academy, Serum, Insulin, Journal, Human, Research, Hypogonadism, Knowledge, Wilson, Waist, Power, Blood, SHBG, Testosterone, Male, BMI, The Journal of Strength and Conditioning Research, Weight loss, Health, Athlete, Dietary supplement, Online shopping, Soft drink, Strength

The latest healthcare news that HealthEd Academy is reporting on is the peer-reviewed study published by Wiley’s Andrology Journal on December 2, 2022, which states that a ketogenic diet increases testosterone levels in obese males by up to 25%.

Key Points: 
  • The latest healthcare news that HealthEd Academy is reporting on is the peer-reviewed study published by Wiley’s Andrology Journal on December 2, 2022, which states that a ketogenic diet increases testosterone levels in obese males by up to 25%.
  • These findings suggest that a low-calorie keto diet can lead to rapid improvements in total testosterone levels associated with weight loss in male obese non-diabetic subjects.
  • The study, ‘Very low-calorie ketogenic diet rapidly augments testosterone levels in non-diabetic obese subjects’ by Angelo Cignarelli et al., that HealthEd Academy is sharing, followed 22 obese males who stuck to a ketogenic diet for 28 days.
  • 34, the study corroborates with the findings reported by Cignarelli as Wilson found that a ketogenic diet (compared to the standard Western diet) significantly increased the men’s total testosterone levels by up to 118ng/dL after 11 weeks.

Hagens Berman Promotes Six Attorneys – Including Five Women – to Partner in 2023

Retrieved on: 
Wednesday, January 4, 2023
Women, Consumer, Professional Services, Legal, DEI (Diversity, Equity and Inclusion), Ignition, Oxford-Whitney Streets Historic District, United States Court of Appeals for the Third Circuit, Veni, vidi, vici, Ezetimibe, HIV, Bosentan, Broiler, Employment, Nasdaq Market Makers Antitrust Litigation, Privacy, Human, Celecoxib, Eye, Adalimumab, Patent, Insulin, Woman, Pharmaceutical industry

Hagens Berman, a global plaintiffs’ class-action law firm, promoted six attorneys – five of whom are women – to partner in 2023, the firm’s 30th year of fighting for the rights of those who need it most.

Key Points: 
  • Hagens Berman, a global plaintiffs’ class-action law firm, promoted six attorneys – five of whom are women – to partner in 2023, the firm’s 30th year of fighting for the rights of those who need it most.
  • “We know that what makes any team strong is its players, and we’re delighted to continue to strengthen our roster of extraordinary partners,” Berman said.
  • The six attorneys come from across four of the firm’s offices, representing exceptional lawyering across a variety of practice areas.
  • Hannah Brennan focuses on drug pricing, consumer access to medications, healthcare fraud, antitrust and patent fraud at the firm’s Boston office.

Global Endocrine Testing Market Report 2022 to 2030: Players Include Agilent Technologies, Bio-Rad Laboratories, Biomerieux and Diasorin - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Health, General Health, Government, Degenerative disease, LabCorp, National Institute of Diabetes and Digestive and Kidney Diseases, Kidney, Consciousness, Research, Digestive, Overweight, TSH, COVID-19, Laboratory, USD, Human body, Mass spectrometry, Pregnancy, Growth, Patient, Gonadotropin, Movement, Infection, American Diabetes Association, Physician, Endocrine system, FSH, Health, Maintenance, Hospital, HCG, Obesity, Thyroid, NIH, Diabetes, NIDDK, Prevalence, WHO, Endocrinology, Collaboration, Vaccine, Pharmaceutical industry, Immunoassay, Insulin

The global endocrine testing market is expected to reach USD 4.79 billion by 2030.

Key Points: 
  • The global endocrine testing market is expected to reach USD 4.79 billion by 2030.
  • The routine endocrine testing in individuals will help in overall maintenance of health and thus this awareness of better health is significantly contributing to the global endocrine testing market growth.
  • Such initiatives will drive the understanding of endocrine function in the human body and will further enable the endocrine testing market growth.
  • The market players are also expanding their regional presence due to various factors that are anticipated to grow the endocrine testing market.

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Retrieved on: 
Thursday, January 5, 2023
Cancer, Pancreas, University, Mouse, Insulin, Glucagon, MD, Type 1, AAV, Diabetes, Factor X, PDX1, Autoimmunity, Division, Wilfrid Sellars, Disease, Patient, Pediatrics, Type 2, Macrophage, Type 2 diabetes, Pitt, University of Pittsburgh School of Medicine, MAF (gene), Patent, Immune system, Human, Gene, Pharmaceutical industry

AUSTIN, Texas, Jan. 5, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. The preclinical technology, GPX-003, is believed to work by rejuvenating diminished beta cells to increase insulin expression by introducing transcription factors controlled by an insulin promoter.

Key Points: 
  • "This marks the Company's third technology license this year supporting our diabetes program, demonstrating the continued strengthening of our intellectual property portfolio, our diabetes program, and our position as a lead innovator in emerging diabetes gene therapies," said Rodney Varner, President and Chief Executive Officer of Genprex.
  • "We are thrilled to have secured multiple cutting edge technologies from Pitt that expand our diabetes gene therapy program and specifically target Type 1 and Type 2 diabetes."
  • Genprex recently announced a license agreement with the University of Pittsburgh for a preclinical technology that transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes, a technology that could be complementary to the Company's GPX-002 diabetes technology.
  • More than 537 million people around the world have diabetes, and in the U.S. alone, there are 37.3 million people with diabetes.

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Retrieved on: 
Wednesday, January 4, 2023
Diabetes, Security (finance), TASE, Absorption, C-peptide, Biotechnology, Patent, Knowledge, Composition, Pressure, Legislation, Glucagon-like peptide-1, Insulin, Research, Pharmaceutical industry, Oramed

 The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).

Key Points: 
  •  The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
  • Oramed Pharmaceuticals (Nasdaq: ORMP) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801 , which is being evaluated in two pivotal Phase 3 trials and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.
  • For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes.

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

Retrieved on: 
Wednesday, January 4, 2023
Human, University, Protein, Autoimmunity, Wilfrid Sellars, Security (finance), Central European, Type 1, Annual report, Patient, Type 2, Food, Squamous cell carcinoma, Medicine, Immune system, Intellectual property, Large-cell lung carcinoma, Honda advanced technology, ATTD, Tumor suppressor gene, Growth, COVID-19, Food and Drug Administration Amendments Act of 2007, Division, Pediatric surgery, Conference, MAF (gene), AAV, MD, Gene, Mouse, Treatment, Pittsburgh, Uncertainty, Pancreas, Pediatrics, Risk, NSCLC, DO, International Conference on Emerging Infectious Diseases, Insulin, Research, Cancer, Pharmaceutical industry, Vaccine, Audit, Diabetes, PDX1

AUSTIN, Texas, Jan. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

Key Points: 
  • "ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community.
  • The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas.
  • Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.